Calcitonin gene-related peptide inhibition: the advent of biologics in rosacea
Calcitonin gene-related peptide inhibition: the advent of biologics in rosacea
About this course
- Released:
- Expires: October 15, 2035
Target Audience
This activity is intended for practicing dermatologists and other physicians involved in the treatment and management of diseases of the skin.
Learning Objective
To consolidate knowledge of the study investigating erenumab as a treatment for refractory flushing and erythema in rosacea.
Accreditation and Designation Statement
Once the test is passed, a certificate of completion will be generated. The learning activity can be added to the Royal College of Physicians' CPD diary as a self-certified entry.
Activity Disclosures
No commercial support has been accepted related to the development or publication of this activity.